NewsRoom Articles - Page 94 of 218

WednesdayDec 14, 2022 12:26 pm

New Study Finds That Hearing Aids May Slow Down Cognitive Decline

New research has found that hearing aids may slow down decline in cognitive function. While prior studies have established that a loss in hearing is a risk factor in the development of dementia, it wasn’t clear if managing hearing loss would slow the progression of cognitive decline — until now. The new study, whose findings were reported in “JAMA Neurology,” provides new evidence demonstrating that hearing loss management could help decrease or even delay a decline in an individual’s cognitive function. For their study, the researchers examined the link between cognitive decline and hearing loss over different durations by conducting…

WednesdayDec 14, 2022 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Anchors Focus and Priority on Berubicin Clinical Development for GBM Treatment

John Climaco, CNS’s CEO, has lauded the company’s progress in Q3 2022, noting the successful expansion of its pivotal Berubicin trial into Europe within the quarter The company hopes to address the unmet need associated with GBM treatment with its lead drug candidate, Berubicin, trusting that the expansion into Europe will be integral to achieving interim analysis by mid-2023 CNS looks to build on the successful patient enrollment and dosing in France, which brings its operational tally to 29 of 68 clinical sites enrolling patients across the United States and Europe, as it works toward interim analysis of clinical trials…

TuesdayDec 13, 2022 12:23 pm

Psoriasis Patients Report Being Embarrassed Because of Flare-Ups in Intertriginous Areas

An analysis conducted on a 2021 poll has released results indicating that most patients suffering from plaque psoriasis have reported symptoms in intertriginous areas, which sometimes prevents them from seeking medical guidance. The researchers looked into the sexual, psychosocial and mental impact of such symptoms on the affected patients and found that roughly two-thirds of patients would like to have therapy options to treat psoriasis in these areas. A team of U.S. researchers, led by Teri Greiling, conducted the analysis of the Harris Poll’s findings and presented their results at this year’s Society of Dermatology Physician Assistants annual meeting. Greiling…

TuesdayDec 13, 2022 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Innovative Inhaled COVID-19 NanoAb Therapy Shows Statistically Significant Efficacy Results in Preclinical Study

The NanoAbs may provide improve upon existing treatments such as Paxlovid, which has several contraindications The company’s pipeline of alpaca-derived NanoAb therapies aims to address diseases with large underserved medical needs, including COVID-19, asthma, psoriasis, and more The global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20%, resulting in a value of $35.42 billion by 2025 A study recently published in JAMA Network found that nearly 15% of COVID-19 patients admitted to 36 Paris University hospitals had contraindications (excluding factors) to Paxlovid, the leading COVID-19 treatment. While Paxlovid…

MondayDec 12, 2022 12:03 pm

Data Shows Increase in Mortality Among Patients with Malignant Brain Tumors

Malignant brain tumors are fast growing and are known to spread to other areas of the brain and spine. These brain tumors are often graded based on how fast they grow and their likelihood of growing back following treatment. The most common type of malignant brain tumor are gliomas, which make up more than 75% of brain tumors. During the 27th annual meeting of the Society for Neuro-Oncology, data on the rise observed in the mortality rate of patients with primary malignant brain tumors was presented. For their research, the investigators conducted an analysis of mortality data obtained from the…

MondayDec 12, 2022 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Has Potential to Make History in Battle Against Deadly Brain Cancer with Berubicin

Glioblastoma, also known as GBM, is a fatal and incurable brain cancer that tends to recur aggressively after initial treatment CNS Pharmaceuticals is a U.S.-based pharmaceutical innovator whose flagship drug candidate, Berubicin, is a potentially pivotal treatment for treating GBM because of its novel apparent ability to cross the blood-brain barrier at effective levels CNS is building upon prior clinical trial outcomes with its global potentially pivotal trial currently registering patients in the United States and Europe Berubicin’s development is being advanced with potential time and cost savings thanks to the FDA’s decision to grant it Fast Track and Orphan…

FridayDec 09, 2022 10:33 am

Existing Drug May Alleviate Side Effects of Cancer Treatment

Cancer treatments often involve surgery, radiation and chemotherapy, which may be administered separately or conjointly, in accordance with a patient’s treatment plan. Commonly prescribed potent chemotherapy drugs include cisplatin, which was first discovered in 1965 at Michigan State University. Cisplatin has proven to be an effective chemotherapy medication that can be useful in the treatment of various solid cancers, including lung, ovarian, testicular, head and neck, bladder and stomach. However, this drug also causes many side effects, including nausea and vomiting; kidney toxicity, which may cause kidney failure in roughly 35% of patients ingesting the drug; and peripheral neuropathy, which…

FridayDec 09, 2022 9:00 am

MetAlert Inc. (MLRT) to Begin Marketing and Distribution of RoomMate(TM) in the U.S., Canada, and the U.K., following Partnership with Sensio Group

MetAlert recently announced the signing of an LOI with Sensio Group for the marketing and distribution of RoomMate, a 3D Infrared supervision product with a fall detection automated monitoring system The company has set out to solve problems unique to individuals afflicted with ADA by creating devices specific to their use cases, and RoomMate is one such product, promising effective remote patient monitoring while maintaining anonymity Through this partnership, MetAlert looks to penetrate the high CAGR projected patient monitoring devices market, valued at $47 billion in 2021 It also looks to leverage the partnership for future up-listing onto a major…

ThursdayDec 08, 2022 12:12 pm

Doing Crossword Puzzles Helps Sharpen Memory Better Than Computer Games

Researchers have discovered that crossword puzzles help to better sharpen memory in older individuals suffering from mild cognitive impairment, in comparison to computer games. While crossword puzzles are popularly used, no research has systematically studied them and their association with mild cognitive impairment until now. Mild cognitive impairment is known to heighten the risk of an individual developing dementia. The study was led by Professor D.P. Devenand of Columbia University and Professor Murali Doraiswamy, director of the Neurocognitive Disorders Program at Duke University School of Medicine. For their study, the researchers recruited more than 100 participants suffering from mild cognitive…

WednesdayDec 07, 2022 1:33 pm

Research Suggests That Gum Disease May Cause Alzheimer’s

Alzheimer’s is a common type of dementia that usually starts with mild memory loss before progressing to loss of the ability to carry on a conversation with another person. Recent studies have found that the disease, which affects parts of the brain that control memory, thought and language, is actually an infection. One such study suggested that gum disease, which starts as bacterial growth in an individual’s mouth, may be the bacterial culprit behind this degenerative condition. This comes after scientists discovered Porphyromonas gingivalis in the brains of deceased individuals who suffered from Alzheimer’s. Porphyromonas gingivalis is a pathogen that…